# N4 Pharma very pleased with EGFR results

- Link: https://www.directorstalkinterviews.com/n4-pharma-very-pleased-with-egfr-results/4121115210
- Published: 2023-04-18T07:26:10+01:00
- Author: Ethan Davis

**N4 Pharma Plc** (LON:N4P), the specialist pharmaceutical company developing Nuvec
®, a novel delivery system for cancer treatments and vaccines, has provided an update
on its ongoing siRNA research work.

The Company has completed the single loading of both the EGFR and BCL-2 siRNA nucleotides
onto Nuvec and has produced good monodisperse formulations at all doses to be investigated.
The single loaded EGFR siRNA has shown strong silencing of the EGFR gene with a 
good dose response curve established which has allowed the Company to identify the
dose it can take into the single loaded EGFR _in vivo_ study.

The next step for EGFR is to measure cell apoptosis to show a relevant _in vitro_
clinical effect.

Supply of siRNA is only available from a few sources and supply issues means N4 
Pharma is still establishing the BCL-2 assay to be used for the _in vitro_ testing.
An initial effect has been seen but to complete the dose response curve more material
is needed to fully establish the assay and determine the doses to move into the 
single loaded _in vivo_ work and double loaded experiments.

The Company has also established the growth curve of the xenograft tumour model 
to be used, so once the BCL-2 _in vitro_ work is complete, the Company will be ready
to start the _in vivo_ studies, as long as supply of the siRNA is not further interrupted.

> **Nigel Theobald, Chief Executive Officer of N4 Pharma, commented:**
> “We are very pleased with the EGFR results which show excellent knockdown of the
> siRNA along with a very clear dose response curve and believe this shows how well
> suited Nuvec® is for working with siRNA.”

Share on:
